Postoperative therapy with infliximab for crohn’s disease: A 2-year prospective randomized multicenter study in japan

Kouhei Fukushima, Akira Sugita, Kitaro Futami, Ken Ichi Takahashi, Satoshi Motoya, Hideaki Kimura, Shusaku Yoshikawa, Yoshitaka Kinouchi, Hideki Iijima, Katsuya Endo, Toshihumi Hibi, Mamoru Watanabe, Iwao Sasaki, Yasuo Suzuki

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Purpose The prevention of postoperative recurrence is a critical issue in surgery for Crohn’s disease. Prospective randomized trials in Western countries have shown that the postoperative use of anti-tumor necrosis factor α-antibodies was effective in reducing the recurrence rate. We investigated the efficacy of infliximab (IFX) for the prevention of postoperative Crohn’s disease recurrence. Methods We performed a prospective randomized multicenter study. Patients who underwent intestinal resection were assigned to groups treated with or without IFX. Immediately after surgery, patients in the IFX group received IFX at 5 mg/ kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years. The primary study outcome was the proportion of patients with endoscopic and/or clinical recurrence at 2 years after surgery. Results Thirty-eight eligible patients participated in this study: 19 in the IFX group and 19 in the non-IFX group. The disease recurrence rate in the IFX group was 52.6% (10/19), which was significantly lower than that in the non-IFX group (94.7% [18/19]). Conclusion The postoperative use of IFX is effective in preventing Crohn’s disease recurrence for 2 years.

Original languageEnglish
Pages (from-to)584-590
Number of pages7
JournalSurgery Today
Issue number6
Publication statusPublished - 2018 Jan 30


  • A prospective randomized multicenter study
  • Crohn’s disease
  • Infliximab
  • Postoperative recurrence


Dive into the research topics of 'Postoperative therapy with infliximab for crohn’s disease: A 2-year prospective randomized multicenter study in japan'. Together they form a unique fingerprint.

Cite this